Catalyst Calendar

Thu, Jul 16, 2026

1 updates

6:45 AM

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli

ataibeckley.com

Mon, Jul 6, 2026

1 updates

ATAI

6:00 AM

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized anxiety disorder (GAD) as a

Enrollment • Phase 2ataibeckley.com

Thu, Jun 25, 2026

1 updates

ATAI

6:00 AM

AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets

AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked Inclusion expands AtaiBeckley’s visibility across U.S.

ataibeckley.com